Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AON-D21

Latest Information Update: 23 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aptarion Biotech
  • Class Anti-infectives; Nucleotide aptamers
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Community-acquired pneumonia
  • Phase I Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 02 Feb 2024 Phase-II clinical trials in Community-acquired pneumonia (Adjunctive treatment) in United Kingdom (IV) (NCT05962606)
  • 27 Jul 2023 Aptarion Biotech plans phase-II trial for Community acquired pneumonia (In adults, In the elderly) in October 2023 (IV) (NCT05962606)
  • 29 Nov 2022 Aptarion Biotech completes a phase I trial (In volunteers) in Germany (IV) (NCT05343819)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top